$FENC
FENNEC PHARMACEUTICALS INC.

2015 Q4 Form 10-K Financial Statement

#000114420417017299 Filed on March 29, 2017

View on sec.gov

Income Statement

Concept 2015 Q4 2015 2014 Q4
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $480.0K $1.630M $630.0K
YoY Change -23.81% -35.32% 90.91%
% of Gross Profit
Research & Development $70.00K $256.0K $170.0K
YoY Change -58.82% -28.29% 88.89%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $550.0K $256.0K $790.0K
YoY Change -30.38% -28.29% 88.1%
Operating Profit -$1.890M
YoY Change -34.31%
Interest Expense $0.00 $1.230M $2.180M
YoY Change -100.0% 75.71% 42.48%
% of Operating Profit
Other Income/Expense, Net $10.00K $1.231M
YoY Change 75.61%
Pretax Income -$540.0K -$658.0K $1.390M
YoY Change -138.85% -50.41% 25.23%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$540.0K -$659.0K $1.390M
YoY Change -138.85% -69.72% 25.23%
Net Earnings / Revenue
Basic Earnings Per Share -$0.06
Diluted Earnings Per Share -$49.36K -$0.06 $140.4K
COMMON SHARES
Basic Shares Outstanding 10.83M shares 9.861M shares
Diluted Shares Outstanding 10.83M shares

Balance Sheet

Concept 2015 Q4 2015 2014 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $940.0K $940.0K $2.310M
YoY Change -59.31% -59.31% 39.16%
Cash & Equivalents $942.0K $940.0K $2.307M
Short-Term Investments
Other Short-Term Assets $1.000K $80.00K $17.00K
YoY Change -94.12% 14.29% 112.5%
Inventory
Prepaid Expenses $48.00K
Receivables
Other Receivables
Total Short-Term Assets $1.020M $1.020M $2.370M
YoY Change -56.96% -56.96% 35.43%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $0.00 $0.00 $2.000K
YoY Change -100.0% 0.0%
TOTAL ASSETS
Total Short-Term Assets $1.020M $1.020M $2.370M
Total Long-Term Assets $0.00 $0.00 $2.000K
Total Assets $1.020M $1.020M $2.372M
YoY Change -57.0% -56.96% 35.39%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $297.0K $300.0K $308.0K
YoY Change -3.57% -3.23% 45.28%
Accrued Expenses $90.00K $90.00K $132.0K
YoY Change -31.82% -30.77% 0.0%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $471.0K $470.0K $1.759M
YoY Change -73.22% -73.3% -45.15%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $471.0K $470.0K $1.759M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $471.0K $470.0K $1.759M
YoY Change -73.22% -73.3% -45.15%
SHAREHOLDERS EQUITY
Retained Earnings -$111.5M -$110.9M
YoY Change 0.59% 2.0%
Common Stock $110.8M $110.2M
YoY Change 0.54% 4.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $548.0K $550.0K $613.0K
YoY Change
Total Liabilities & Shareholders Equity $1.019M $1.020M $2.372M
YoY Change -57.04% -56.96% 35.39%

Cashflow Statement

Concept 2015 Q4 2015 2014 Q4
OPERATING ACTIVITIES
Net Income -$540.0K -$659.0K $1.390M
YoY Change -138.85% -69.72% 25.23%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$420.0K -$1.860M -$470.0K
YoY Change -10.64% 9.48% 6.82%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00 $0.00
YoY Change
Cash From Investing Activities $0.00 $0.00 $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $0.00
YoY Change -100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 500.0K 2.180M
YoY Change -100.0% -78.66% 38.85%
NET CHANGE
Cash From Operating Activities -420.0K -1.860M -470.0K
Cash From Investing Activities 0.000 0.000 0.000
Cash From Financing Activities 0.000 500.0K 2.180M
Net Change In Cash -420.0K -1.360M 1.710M
YoY Change -124.56% -311.18% 51.33%
FREE CASH FLOW
Cash From Operating Activities -$420.0K -$1.860M -$470.0K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2015Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
82000 USD
CY2016Q4 us-gaap Liabilities
Liabilities
402000 USD
CY2015Q4 us-gaap Liabilities
Liabilities
471000 USD
CY2016Q4 us-gaap Common Stock Value
CommonStockValue
74515000 USD
CY2015Q4 us-gaap Common Stock Value
CommonStockValue
69401000 USD
CY2015Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
41437000 USD
CY2016Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-114322000 USD
CY2016Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
125000 USD
CY2015Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
297000 USD
CY2016Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
33000 USD
CY2016Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
42134000 USD
CY2015Q4 us-gaap Liabilities Current
LiabilitiesCurrent
471000 USD
CY2015 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-952000 USD
CY2016Q4 us-gaap Liabilities Current
LiabilitiesCurrent
402000 USD
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
942000 USD
CY2015 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.06
CY2016 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.22
CY2016 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
5108000 USD
CY2016 us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
-33000 USD
CY2015 us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
28000 USD
CY2015 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-16000 USD
CY2015 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-11000 USD
CY2015 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-40000 USD
CY2015 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 USD
CY2016 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
6000 USD
CY2015 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
48000 USD
CY2016 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
102000 USD
CY2015 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
449000 USD
CY2016 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
5000000 USD
CY2016Q4 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
3926000 USD
CY2015Q4 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
942000 USD
CY2015 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
294000 USD
CY2016 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-1018000 USD
CY2016 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-2789000 USD
CY2015 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-658000 USD
CY2016 fencf Expected Provision For Recovery Of Income Tax
ExpectedProvisionForRecoveryOfIncomeTax
-739000 USD
CY2015 fencf Expected Provision For Recovery Of Income Tax
ExpectedProvisionForRecoveryOfIncomeTax
-174000 USD
CY2016 fencf Permanent Difference
PermanentDifference
156000 USD
CY2015 fencf Permanent Difference
PermanentDifference
-301000 USD
CY2016 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
583000 USD
CY2015 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
-1297000 USD
CY2016 us-gaap Income Tax Reconciliation Repatriation Of Foreign Earnings
IncomeTaxReconciliationRepatriationOfForeignEarnings
0 USD
CY2015 us-gaap Income Tax Reconciliation Repatriation Of Foreign Earnings
IncomeTaxReconciliationRepatriationOfForeignEarnings
0 USD
CY2016Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
3972000 USD
CY2015 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
10827000 shares
CY2015Q4 us-gaap Other Assets Current
OtherAssetsCurrent
1000 USD
CY2015Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-111533000 USD
CY2015Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
1243000 USD
CY2015Q4 us-gaap Stockholders Equity
StockholdersEquity
548000 USD
CY2016Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
43000 USD
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2307000 USD
CY2015 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
497000 USD
CY2016 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
2000 USD
CY2016 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-54000 USD
CY2016 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
0 USD
CY2015 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
0 USD
CY2016 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
2984000 USD
CY2015 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-1365000 USD
CY2016 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
33000 USD
CY2016Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
244000 USD
CY2015Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1019000 USD
CY2016 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
12765000 shares
CY2016 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
88000 USD
CY2015 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
0 USD
CY2016 us-gaap Share Based Compensation
ShareBasedCompensation
615000 USD
CY2015 us-gaap Share Based Compensation
ShareBasedCompensation
97000 USD
CY2016 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-2124000 USD
CY2015 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-1862000 USD
CY2016 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
0 USD
CY2015 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
0 USD
CY2016 fencf Effective Income Tax Rate Reconciliation Effect Of Noncapital Losses Expired
EffectiveIncomeTaxRateReconciliationEffectOfNoncapitalLossesExpired
0 USD
CY2015 fencf Effective Income Tax Rate Reconciliation Effect Of Noncapital Losses Expired
EffectiveIncomeTaxRateReconciliationEffectOfNoncapitalLossesExpired
1318000 USD
CY2016 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2015 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2016 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-1771000 USD
CY2016 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.2650 pure
CY2015 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.2650 pure
CY2016 fencf Income Tax Reconciliation Tax Credits Other Adjustments
IncomeTaxReconciliationTaxCreditsOtherAdjustments
1000 USD
CY2016 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
-1000 USD
CY2015 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
4000 USD
CY2015 fencf Income Tax Reconciliation Tax Credits Other Adjustments
IncomeTaxReconciliationTaxCreditsOtherAdjustments
450000 USD
CY2016Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0 USD
CY2015Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0 USD
CY2016Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
3926000 USD
CY2016Q4 us-gaap Derivative Fair Value Of Derivative Liability
DerivativeFairValueOfDerivativeLiability
33000 USD
CY2016Q4 us-gaap Cash
Cash
68000 CAD
CY2016Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
575000 USD
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
3000 USD
CY2016 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
280000 USD
CY2016 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
12765000 shares
CY2015 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
10827000 shares
CY2016 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
12765000 shares
CY2015 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
10827000 shares
CY2016 dei Document Type
DocumentType
10-K
CY2016 dei Amendment Flag
AmendmentFlag
false
CY2016 dei Document Period End Date
DocumentPeriodEndDate
2016-12-31
CY2016 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2016
CY2016 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2016 dei Entity Registrant Name
EntityRegistrantName
FENNEC PHARMACEUTICALS INC.
CY2016 dei Entity Central Index Key
EntityCentralIndexKey
0001211583
CY2016 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2016 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2016 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2016 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2016 dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
CY2016Q2 dei Entity Public Float
EntityPublicFloat
10156736 USD
CY2016 dei Trading Symbol
TradingSymbol
FENCF
CY2017Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
13642567 shares
CY2015Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2016Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2016Q4 us-gaap Common Stock No Par Value
CommonStockNoParValue
0
CY2015Q4 us-gaap Common Stock No Par Value
CommonStockNoParValue
0
CY2016Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
13643000 shares
CY2016Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
13643000 shares
CY2015Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
10940000 shares
CY2015Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
10940000 shares
CY2015 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
0 USD
CY2016 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
40000 USD
CY2014Q4 us-gaap Stockholders Equity
StockholdersEquity
613000 USD
CY2015 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
97000 USD
CY2015 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
48000 USD
CY2015 fencf Stock Issued During Period Value Stock Warrants Exercised
StockIssuedDuringPeriodValueStockWarrantsExercised
449000 USD
CY2016 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
6000 USD
CY2016 fencf Stock Issued During Period Value Stock Warrants Exercised
StockIssuedDuringPeriodValueStockWarrantsExercised
102000 USD
CY2016 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
5000000 USD
CY2016Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
23592000 USD
CY2015Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
23010000 USD
CY2016 fencf Derecognized Of Payable Reversed Into Expenses
DerecognizedOfPayableReversedIntoExpenses
79000 USD
CY2016Q3 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
40000 USD
CY2016Q3 fencf Disposal Of Asset Percentage Of Revenue Sharing
DisposalOfAssetPercentageOfRevenueSharing
0.05 pure
CY2016Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
1383000 shares
CY2016Q4 us-gaap Cash
Cash
51000 USD
CY2016Q4 us-gaap Derivative Liabilities
DerivativeLiabilities
33000 USD
CY2015Q4 us-gaap Derivative Liabilities
DerivativeLiabilities
82000 USD
CY2016 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P4Y7M2D
CY2016Q4 fencf Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding And Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAndExercisableNumber
1428000 shares
CY2016 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P7Y
CY2015 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P7Y
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2016 us-gaap Description Of Difference Between Reported Amount And Reporting Currency Denominated Amount
DescriptionOfDifferenceBetweenReportedAmountAndReportingCurrencyDenominatedAmount
exchange rate of $CAD/$USD 0.7881
CY2016 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-14000 USD
CY2015 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-9000 USD
CY2016 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
72000 USD
CY2016 us-gaap Use Of Estimates
UseOfEstimates
<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><b><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Use of estimates</b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify">The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that impact the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the consolidated financial statements and the reported amounts of revenue and expense during the reporting period.&#160;Significant estimates include the valuation of derivative warrant liability and the valuation of stock based compensation.&#160;Actual results could differ from those estimates.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2015 fencf Increase In Common Stock Value
IncreaseInCommonStockValue
248000 USD
CY2016Q4 us-gaap Deferred Tax Assets Valuation Allowance Current
DeferredTaxAssetsValuationAllowanceCurrent
23592000 USD
CY2015Q4 us-gaap Deferred Tax Assets Valuation Allowance Current
DeferredTaxAssetsValuationAllowanceCurrent
23010000 USD

Files In Submission

Name View Source Status
0001144204-17-017299-index-headers.html Edgar Link pending
0001144204-17-017299-index.html Edgar Link pending
0001144204-17-017299.txt Edgar Link pending
0001144204-17-017299-xbrl.zip Edgar Link pending
fencf-20161231.xml Edgar Link completed
fencf-20161231.xsd Edgar Link pending
fencf-20161231_cal.xml Edgar Link unprocessable
fencf-20161231_def.xml Edgar Link unprocessable
fencf-20161231_lab.xml Edgar Link unprocessable
fencf-20161231_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
pg1img1_ex99-1.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
v461464_10k.htm Edgar Link pending
v461464_ex31-1.htm Edgar Link pending
v461464_ex31-2.htm Edgar Link pending
v461464_ex32-1.htm Edgar Link pending
v461464_ex99-1.htm Edgar Link pending